•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced the appointment of Jesper Høiland as Head of Strategy. Høiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including expertise in obesity and metabolic disease.
In the newly created adviser role, Høiland will shape Rani’s corporate and pipeline strategy. His responsibilities include prioritizing internal programs, evaluating new therapeutic opportunities, and supporting the company’s partnering and business development efforts. He will work closely with the executive team to align development decisions with long-term strategic and market considerations.
“Jesper is a highly respected leader with a rare combination of strategic insight and deep commercial experience, and we are thrilled to welcome him as Head of Strategy,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “As we continue to expand our pipeline and evaluate new opportunities for the RaniPill® platform, Jesper will play a critical role in helping us prioritize the most impactful programs and align our strategy with areas of greatest clinical and market potential. His experience across global organizations and therapeutic areas, along with his strong industry relationships, will be invaluable as we advance our partnering strategy and continue to build a differentiated pipeline.”
Høiland brings more than three decades of experience in global pharmaceutical leadership, including strategy development, organization building, and guiding the development and commercialization of innovative therapies. Most recently, he served as Global Commercial Officer at Ascendis Pharma, overseeing worldwide commercial strategy across established and emerging markets.
Prior to Ascendis, he served as President and Chief Executive Officer of Radius Health. Earlier in his career, he held leadership roles in Novo Nordisk’s U.S. operations, including President and Executive Vice President, where he led key launches and commercial strategy across the company’s metabolic portfolio.
Throughout his career, Høiland has contributed to the development and commercialization of multiple therapies, including Novo Nordisk’s insulin analog portfolio and Tresiba®, as well as Tymlos® and Skytrofa®.
Høiland said he was drawn to Rani’s platform and the opportunity it creates across therapeutic areas. He highlighted the potential of oral delivery of biologics to reshape treatment paradigms and referenced Rani’s preclinical semaglutide and GLP-1/GLP-2 data announced last year.
“What attracted me to Rani is the strength of its platform and the breadth of opportunity it creates across multiple therapeutic areas,” said Høiland. “The ability to deliver biologics orally has the potential to reshape treatment paradigms, and I believe Rani is uniquely positioned to capitalize on that opportunity. In particular, I was extremely impressed by the preclinical semaglutide and GLP-1/GLP-2 data Rani announced last year and how well Rani is positioned in the obesity space. My focus will be on helping the company prioritize the right programs, identifying the most valuable opportunities for the platform, and supporting strategic partnerships that can bring these therapies to patients globally. I look forward to working with the team as Rani continues to advance its pipeline and execute on its long-term strategy.”
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The company has developed the RaniPill® capsule, a proprietary and patented platform intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has conducted preclinical and clinical studies evaluating safety, tolerability, and bioavailability using the RaniPill® capsule technology.
The company noted that statements in the press release that are not historical facts are forward-looking statements under the Private Securities Litigation Reform Act of 1995. These include statements regarding Rani’s ability to advance its clinical pipeline, the potential for the RaniPill® platform, the identification and prioritization of pipeline opportunities, and the potential for future partnerships and benefits of oral biologic therapies. The company said actual results may differ materially due to risks and uncertainties, including those described in its filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings.
Forward-looking statements speak only as of the date they are made, and Rani undertakes no obligation to update them except as required by law.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
